Please login to the form below

Not currently logged in
Email:
Password:

treatment

This page shows the latest treatment news and features for those working in and with pharma, biotech and healthcare.

Amarin hits jackpot with astonishing heart benefits from fish oil product

Amarin hits jackpot with astonishing heart benefits from fish oil product

Given Vascepa is affordably priced, orally administered and has a favourable safety profile, REDUCE-IT results could lead to a new paradigm in treatment to further reduce the significant cardiovascular risk

Latest news

  • CHMP backs Spark’s Luxturna, but rejects Sarepta again CHMP backs Spark’s Luxturna, but rejects Sarepta again

    CHMP backs Spark’ s Luxturna, but rejects Sarepta again. Contrasting fortunes for rare disease treatments. ... controversy by setting the price of the treatment at $425, 000 per eye.

  • After Lucentis setback, Novartis trumpets data on follow-up drug After Lucentis setback, Novartis trumpets data on follow-up drug

    After Lucentis setback, Novartis trumpets data on follow-up drug. Next gen eye treatment offers less frequent dosing. ... That involves using VEGF drugs to clear the retina of fluid and haemorrhages for the first three months, and then extending

  • CRUK forges £30m ‘post-Brexit’ R&D alliance CRUK forges £30m ‘post-Brexit’ R&D alliance

    And finally, in Spain, the Clinica Universidad de Navarra is getting £4.8m to investigate mechanisms of resistance in blood cancers and identify new treatment approaches. ... Research must be prioritised as the UK builds a new relationship with the EU,

  • Bayer roll-out of haemophilia drug Jivi gathers pace Bayer roll-out of haemophilia drug Jivi gathers pace

    Bayer’s existing Factor VIII treatments – short-acting Kogenate and Kovaltry – had combined sales of 967m last year. ... for treatment with the once-monthly injection, could hit sales of Factor VIII products across the board.

  • NHS wins legal fight with pharma over off-label Avastin NHS wins legal fight with pharma over off-label Avastin

    We are delighted by today’s ruling that clearly shows the northern CCGs acted lawfully in introducing the preferred treatment option for Avastin. ... The two pharmaceutical companies also argued that the ‘compounding’or adaptation of Avastin for

More from news
Approximately 7 fully matching, plus 1,436 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 2 fully matching, plus 479 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 212 partially matching documents found.

Latest from PMHub

  • The gene therapy revolution

    However, in most areas where genetic treatments are being developed, for instance haemophilia and DMD, there will be far more than 12 patients per year seeking treatment. ... How should patients be selected for treatment, who comes first, and who makes

  • More tell, less sell: HCP-centric comms

    Patients are more likely than ever to research their condition and potential treatments before seeing their doctor,[3] meaning patients need reliable sources of information so that they are well-informed ... currently treatable or amenable to wider

  • Making a Difference - The Future of Pharma

    4 BN treatments to the developing world in 2014.

  • Moving away from pharma’s paternalistic approach

    Silva said, “ Patients increasingly want to contribute to the development of better medicines and better services to support new treatments, but often the infrastructure to involve patients in a structural way

  • Genetic counsellors: the new healthcare influencers?

    This pioneering policy will help match patients with existing therapies or clinical trials, which are likely to improve their cancer treatment. ... The training resulted in faster treatment decisions and more efficient use of resources.

More from PMHub
Approximately 22 fully matching, plus 441 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Solaris Health

The beauty of detail: an effective, compelling medical communications campaign requires each component to be carefully planned, expertly crafted and...

Latest intelligence

Solaris Health looks at the gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...

Infographics